Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Starts Domestic Study For Farletuzumab For Ovarian Cancer

This article was originally published in PharmAsia News

Executive Summary

Eisai started a Japanese domestic clinical study for farletuzumab on patients with ovarian cancer. The drug is developed by Eisai U.S. subsidiary Morphotek, which Eisai acquired in 2007. Farletuzumab is an anti-folate receptor alpha mAb undergoing Phase III trials in the U.S. and Europe for ovarian cancer. Eisai is planning a cross-regional study aiming to submit new drug applications in Japan and China as early as 2012.This is the second international clinical study for the company, which has also conducted a simultaneous study in Japan, the U.S. and Europe for severe sepsis drug eritoran. (Click here for more - Japanese language)"Eisai To Develop Domestic Antibody Drug For Ovarian Cancer" - Chemical Daily (8/25/2010)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC075758

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel